Elucidating the Interactions of Fluoxetine with Human Transferrin Employing Spectroscopic, Calorimetric, and in Silico Approaches: Implications of a Potent Alzheimer's Drug
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Khan, M.S. | - |
dc.contributor.author | Shahwan, M. | - |
dc.contributor.author | Shamsi, A. | - |
dc.contributor.author | Alhumaydhi, F.A. | - |
dc.contributor.author | Alsagaby, S.A. | - |
dc.contributor.author | Al, Abdulmonem W. | - |
dc.contributor.author | Abdullaev, B. | - |
dc.contributor.author | Yadav, D.K. | - |
dc.date.accessioned | 2022-05-10T02:40:09Z | - |
dc.date.available | 2022-05-10T02:40:09Z | - |
dc.date.created | 2022-04-30 | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 2470-1343 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84228 | - |
dc.description.abstract | Neurodegenerative complexities, such as dementia, Alzheimer's disease (AD), and so forth, have been a crucial health concern for ages. Transferrin (Tf) is a chief target to explore in AD management. Fluoxetine (FXT) presents itself as a potent anti-AD drug-like compound and has been explored against several diseases based on the drug repurposing readings. The present study delineates the binding of FXT to Tf employing structure-based docking, molecular dynamics (MD) simulations, and principal component analysis (PCA). Docking results showed the binding of FXT with Tf with an appreciable binding affinity, making various close interactions. MD simulation of FXT with Tf for 100 ns suggested their stable binding without any significant structural alteration. Furthermore, fluorescence-based binding revealed a significant interaction between FXT and Tf. FXT binds to Tf with a binding constant of 5.5 × 105 M-1. Isothermal titration calorimetry (ITC) advocated the binding of FXT to Tf as spontaneous in nature, affirming earlier observations. This work indicated plausible interactions between FXT and Tf, which are worth considering for further studies in the clinical management of neurological disorders, including AD. © 2022 The Authors. Published by American Chemical Society. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | American Chemical Society | - |
dc.relation.isPartOf | ACS Omega | - |
dc.title | Elucidating the Interactions of Fluoxetine with Human Transferrin Employing Spectroscopic, Calorimetric, and in Silico Approaches: Implications of a Potent Alzheimer's Drug | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000783601100079 | - |
dc.identifier.doi | 10.1021/acsomega.2c00182 | - |
dc.identifier.bibliographicCitation | ACS Omega, v.7, no.10, pp.9015 - 9023 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85126763315 | - |
dc.citation.endPage | 9023 | - |
dc.citation.startPage | 9015 | - |
dc.citation.title | ACS Omega | - |
dc.citation.volume | 7 | - |
dc.citation.number | 10 | - |
dc.contributor.affiliatedAuthor | Yadav, D.K. | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | HIPPOCAMPAL NEUROGENESIS | - |
dc.subject.keywordPlus | STRUCTURAL BASIS | - |
dc.subject.keywordPlus | FORCE-FIELD | - |
dc.subject.keywordPlus | IRON | - |
dc.subject.keywordPlus | ANTIDEPRESSANT | - |
dc.subject.keywordPlus | DEPRESSION | - |
dc.subject.keywordPlus | DYNAMICS | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | FERRITIN | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.